Li C, Li M, Wang Z
Sci Rep. 2025; 15(1):8538.
PMID: 40074828
PMC: 11903960.
DOI: 10.1038/s41598-025-93518-z.
Sheashaa H, Mousa H, Abbas M, Farina J, Awad K, Pereyra M
Biomolecules. 2025; 15(2).
PMID: 40001465
PMC: 11853184.
DOI: 10.3390/biom15020162.
Konieczynska M, Natorska J, Zabczyk M, Undas A
Arch Med Sci. 2025; 20(6):1770-1783.
PMID: 39967936
PMC: 11831339.
DOI: 10.5114/aoms/197357.
Li J, Ma B, Fang Q, Wang J, Sun Y, Ding H
Lipids Health Dis. 2025; 24(1):49.
PMID: 39953584
PMC: 11827131.
DOI: 10.1186/s12944-025-02467-z.
Ramirez-Melo L, Estrada-Luna D, Rubio-Ruiz M, Castaneda-Ovando A, Fernandez-Martinez E, Jimenez-Osorio A
Int J Mol Sci. 2025; 26(3).
PMID: 39940892
PMC: 11817739.
DOI: 10.3390/ijms26031125.
Lipoprotein(a) Response to Dietary Saturated Fat Reduction: Relationship to Apolipoprotein(a) Size Polymorphism in African Americans.
Law H, Myagmarsuren M, Bang H, Zhang W, Lefevre M, Berglund L
Nutrients. 2025; 17(3).
PMID: 39940285
PMC: 11820444.
DOI: 10.3390/nu17030426.
Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study.
Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J
Ann Med. 2025; 57(1):2454975.
PMID: 39898960
PMC: 11792142.
DOI: 10.1080/07853890.2025.2454975.
Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High-Grade Prostate Cancer and Men At-Risk of Prostate Cancer.
Bergeron A, Wong-Chong E, Joncas F, Castonguay C, Calon F, Seidah N
Cancer Med. 2025; 14(3):e70587.
PMID: 39888285
PMC: 11783234.
DOI: 10.1002/cam4.70587.
The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease.
Li Q, Xu S, Shen J, Sun F
Sci Rep. 2025; 15(1):1720.
PMID: 39799177
PMC: 11724887.
DOI: 10.1038/s41598-025-86154-0.
Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.
Krzesinska A, Marlega-Linert J, Chyla-Danil G, Marcinkowska M, Rogowska P, Stumska K
Int J Mol Sci. 2025; 25(24.
PMID: 39769362
PMC: 11676408.
DOI: 10.3390/ijms252413597.
Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases.
Li Z, Zhu L, Xu Y, Zhang Y, Liu Y, Sun H
Biomedicines. 2025; 12(12.
PMID: 39767636
PMC: 11726846.
DOI: 10.3390/biomedicines12122729.
Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma.
Liu J, Liu Z, Xu D, Zhou T, Li A, Hu J
Int J Gen Med. 2025; 17:6465-6478.
PMID: 39742033
PMC: 11687294.
DOI: 10.2147/IJGM.S501401.
Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study.
Eid W, Sapp E, Conroy C, Bessinger C, Moody C, Yadav R
Am J Prev Cardiol. 2024; 21:100895.
PMID: 39720768
PMC: 11666892.
DOI: 10.1016/j.ajpc.2024.100895.
Measuring Lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin.
Swearingen C, Sloan J, Rhodes G, Siegel R, Bivi N, Qian Y
J Lipid Res. 2024; 66(1):100723.
PMID: 39647781
PMC: 11761857.
DOI: 10.1016/j.jlr.2024.100723.
The Impact of Diet on Lipoprotein(a) Levels.
Stojko M, Spychal A, Nikel K, Kolodziej R, Zalejska-Fiolka J
Life (Basel). 2024; 14(11).
PMID: 39598201
PMC: 11595969.
DOI: 10.3390/life14111403.
Lp(a): A Rapidly Evolving Therapeutic Landscape.
Anchouche K, Thanassoulis G
Curr Atheroscler Rep. 2024; 27(1):7.
PMID: 39576403
DOI: 10.1007/s11883-024-01252-0.
Lipid nanoparticle delivery of TALEN mRNA targeting LPA causes gene disruption and plasma lipoprotein(a) reduction in transgenic mice.
Garcia D, Pierre A, Quirino L, Acharya G, Vasudevan A, Pei Y
Mol Ther. 2024; 33(1):90-103.
PMID: 39563033
PMC: 11764125.
DOI: 10.1016/j.ymthe.2024.11.020.
Association of Lipoprotein(a) With Severe Degenerative Aortic Valve Stenosis.
Kim A, Ahn J, Kang D, Jun T, Sun B, Kim H
JACC Asia. 2024; 4(10):751-760.
PMID: 39553905
PMC: 11561479.
DOI: 10.1016/j.jacasi.2024.07.007.
Global Standardization of Lipid/Lipoprotein Testing.
Miida T
Juntendo Iji Zasshi. 2024; 70(5):324-331.
PMID: 39545227
PMC: 11560336.
DOI: 10.14789/jmj.JMJ24-0019-P.
Clinical and angiographic characteristics of patients with familial hypercholesterolemia presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Elmaghraby K, Abdel-Galeel A, Osman A, Hasan-Ali H, Abdelmegid M
Sci Rep. 2024; 14(1):27098.
PMID: 39511296
PMC: 11543695.
DOI: 10.1038/s41598-024-77656-4.